Exploring the clinical and social determinants of prescribing anticholinergic medication for Chinese patients with schizophrenia

Human Psychopharmacology

Volumn 22, Issue 3, 2007, Pages 173-180

  Yu Tao, Xiang ^a,b,c   Yong Zhen, Weng ^b   Chi Ming, Leung ^a   Wai Kwong, Tang ^a   Ungvari, Gabor Sandor ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^b CAPITAL MEDICAL UNIVERSITY   (China)

^c SHATIN HOSPITAL   (Hong Kong)

Author keywords

Anticholinergic medication; China; Prescription patterns; Schizophrenia

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; CHLORPROMAZINE; CHOLINERGIC RECEPTOR BLOCKING AGENT; CLOZAPINE; NEUROLEPTIC AGENT; PSYCHOTROPIC AGENT; TRIHEXYPHENIDYL;

ADULT; ARTICLE; CHINA; CHINESE; CLINICAL FEATURE; CONTROLLED STUDY; CULTURAL FACTOR; DEMOGRAPHY; DISEASE ACTIVITY; DOSE RESPONSE; ETHNICITY; EXTRAPYRAMIDAL SYMPTOM; FEMALE; HEALTH INSURANCE; HONG KONG; HUMAN; INTERVIEW; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; OUTPATIENT; PATIENT SELECTION; POLYPHARMACY; PRESCRIPTION; PRIORITY JOURNAL; SCHIZOPHRENIA; SOCIAL ASPECT;

ADOLESCENT; ADULT; ANTIPSYCHOTIC AGENTS; CHINA; CHOLINERGIC ANTAGONISTS; FEMALE; HUMANS; MALE; MIDDLE AGED; PRESCRIPTIONS, DRUG; RETROSPECTIVE STUDIES; SCHIZOPHRENIA; STATISTICS, NONPARAMETRIC; TREATMENT OUTCOME;

EID: 34248389380     PISSN: 08856222     EISSN: 10991077     Source Type: Journal    
DOI: 10.1002/hup.830     Document Type: Article

References (47)

1. APA. Diagnostic and Statistical Manual of Mental Disorders, 4th edn. American Psychiatric Association: Washington, 1994.
2. Barbui C, Nose M, Bindman J, et al. 2005. Sex differences in the subjective tolerability of antipsychotic drugs. J Clin Psychopharmacol 25: 521-526.
3. Barnes TR. 1989. A rating scale for drug-induced akathisia. Br J Psychiatry 154: 672-676.
4. Bergen J, Kitchin R, Berry G. 1992. Predictors of the course of tardive dyskinesia in patients receiving neuroleptics. Biol Psychiatry 32: 580-594.
5. Binder RL, Kazamatsuri H, Nishimura T, McNiel DE. 1987. Tardive dyskinesia and neuroleptic-induced parkinsonism in Japan. Am J Psychiatry 144: 1494-1496.
6. Brebion G, Bressan RA, Amador X, Malaspina D, Gorman JM. 2004. Medications and verbal memory impairment in schizophrenia: the role of anticholinergic drugs. Psychol Med 34: 369-374.
7. Caradoc-Davies G, Menkes DB, Clarkson HO, Mullen PE. 1986. A study of the need for anticholinergic medication in patients treated with long-term antipsychotics. Aust N Z J Psychiatry 20: 225-232.
8. Carnahan RM, Lund BC, Perry PJ, Chrischilles EA. 2006. Increased risk of extrapyramidal side-effect treatment associated with atypical antipsychotic polytherapy. Acta Psychiatr Scand 113: 135-141.
9. Drimer T, Shahal B, Barak Y. 2004. Effects of discontinuation of long-term anticholinergic treatment in elderly schizophrenia patients. Int Clin Psychopharmacol 19: 27-29.
10. Gerlach J, Rasmussen PT, Hansen L, Kristjansen P. 1977. Anti-parkinsonian agents and long-term neuroleptic treatment. Effect of G 31.406, orphenadrine, and placebo on parkinsonism, schizophrenic symptoms, depression and anxiety. Acta Psychiatr Scand 55: 251-260.
11. Goff DC, Arana GW, Greenblatt DJ, et al. 1991. The effect of benztropine on haloperidol-induced dystonia, clinical efficacy and pharmacokinetics: a prospective, double-blind trial. J Clin Psychopharmacol 11: 106-112.
12. Gray R, Gournay K. 2000. What can we do about acute extrapyramidal symptoms? J Psychiatr Ment Health Nurs 7: 205-211.
13. Greil W, Haag H, Rossnagl G, Ruther E. 1984. Effect of anticholinergics on tardive dyskinesia. A controlled discontinuation study. Br J Psychiatry 145: 304-310.
14. Hospital Authority of Hong Kong. 2005. Clinical Practice Guideline for Schizophrenia. Hong Kong: Hospital Authority.
15. Kane JM. 1996. Schizophrenia. N Engl J Med 334: 34-41.
16. Kane JM, Evans DL, Fiester SJ, et al. 1992. Psychopharmacological screening criteria. APA Committee on Research on Psychiatric Treatments. J Clin Psychiatry 53: 184-196.
17. Kilian R, Angermeyer MC. 2005. The effects of antipsychotic treatment on quality of life of schizophrenic patients under naturalistic treatment conditions: an application of random effect regression models and propensity scores in an observational prospective trial. Qual Life Res 14: 1275-1289.
18. Kolakowska T, Williams AO, Ardern M, Reveley MA. 1986. Tardive dyskinesia in schizophrenics under 60 years of age. Biol Psychiatry 21: 161-169.
19. Lake CR, Casey DE, McEvoy JP, Siris SG, Boyer WF, Simpson G. 1986. Anticholinergic prophylaxis in young adults treated with neuroleptic drugs. Psychopharmacol Bull 22: 981-984.
20. Land W, Pinsky D, Salzman C. 1991. Abuse and misuse of anticholinergic medications. Hosp Community Psychiatry 42: 580-581.
21. Lavin MR, Rifkin A. 1991. Prophylactic antiparkinson drug use: II. Withdrawal after long-term maintenance therapy. J Clin Pharmacol 31: 769-777.
22. Li SC, Jiang KD, Tao MY, Xiao S. 1997. Use of antipsychotic drugs in psychiatric outpatients (in Chinese). J Clin Psychol Med 7: 326-328.
23. Lobana A, Mattoo SK, Basu D, Gupta N. 2001. Quality of life in schizophrenia in India: comparison of three approaches. Acta Psychiatr Scand 104: 51-55.
24. NICE. 2003. Schizophrenia. In Full National Clinical Guideline on Core Intervention in Primary and Secondary Care, Cromwell Press: Trowbridge, Wiltshire, UK, (also http://www.nice.org.uk/guidance/CG1/ guidance/pdf/English)
25. Overall JE, Beller SA. 1984. The Brief Psychiatric Rating Scale (BPRS) in geropsychiatric research: I. Factor structure on an inpatient unit. J Gerontol 39: 187-193.
26. Perris C, Dimitrijevic P, Jacobsson L, Paulsson P, Rapp W, Froberg H. 1979. Tardive dyskinesia in psychiatric patients treated with neuroleptics. Br J Psychiatry 135: 509-514.
27. Rifkin A, Quitkin F, Kane J, Struve F, Klein DF. 1978. Are prophylactic antiparkinson drugs necessary? A controlled study of procyclidine withdrawal. Arch Gen Psychiatry 35: 483-489.
28. Schuklenk U. 2001. Helsinki declaration revisions. Issues Med Ethics 9: 29.
29. Shen YC. 2002. Psychiatry. People's medical publishing house: Beijing.
30. Sim K, Su A, Fujii S, et al. 2004a. Antipsychotic polypharmacy in patients with schizophrenia: a multicentre comparative study in East Asia. Br J Clin Pharmacol 58: 178-183.
31. Sim K, Su A, Leong JY, et al. 2004b. High dose antipsychotic use in schizophrenia: findings of the REAP (research on east Asia psychotropic prescriptions) study. Pharmacopsychiatry 37: 175-179.
32. Simpson GM, Angus JW. 1970. A rating scale for extrapyramidal side effects. Acta Psychiatr Scand Suppl 212: 11-19.
33. Tandon R, Dequardo JR. 1995. Treatment of schizophrenia with anticholinergic medications. Am J Psychiatry 152: 814-815.
34. Taylor D. 2000. Low dose typical antipsychotics - a brief evaluation. Psychiatr Bull 24: 465-468.
35. Taylor D, Paton C, Kerwin R. The Maudsley Prescribing Guidelines. Martin Dunitz: London, 2003.
36. Ungvari GS, Chow LY, Chiu HF, Ng FS, Leung T. 1997. Modifying psychotropic drug prescription patterns: a follow-up survey. Psychiatry Clin Neurosci 51: 309-314.
37. Ungvari GS, Chiu HF, Lam LC, et al. 1999. Gradual withdrawal of long-term anticholinergic antiparkinson medication in Chinese patients with chronic schizophrenia. J Clin Psychopharmacol 19: 141-148.
38. Ungvari GS, Chung YG, Chee YK, Fung-Shing N, Kwong TW, Chiu HF. 2002. The pharmacological treatment of schizophrenia in Chinese patients: a comparison of prescription patterns between 1996 and 1999. Br J Clin Pharmacol 54: 437-444.
39. Weng YZ, Xu MJ, Li DL, Guo FY, Huang Q, Fu T. 2001. Assessment of expressed emotion in family members of schizophrenic patients in Beijing. Mod Rehabil 5: 39-42.
40. Wheeler A. 2006. Atypical antipsychotic use for adult outpatients in New Zealand's Auckland and Northland regions. N Z Med J 119: U2055.
41. Whicher E, Riley J. 2003: Audit of antipsychotic and anticholinergic prescribing: Leeds CMHT 2000-1. BMA News 28: 156.
42. WHO. 1990. Prophylactic use of anticholinergics in patients on long-term neuroleptic treatment. A consensus statement. World Health Organization heads of centres collaborating in WHO co-ordinated studies on biological aspects of mental illness. Br J Psychiatry 156: 412.
43. WHO. 1998. Development of the World Health Organization WHO-QOL-BREF quality of life assessment. The WHOQOL Group. Psychol Med 28: 551-558.
44. Work Group on Schizophrenia. 2004. Practice guideline for the treatment of patients with schizophrenia. In APA Practice Guidelines, 2nd edn, American Psychiatric Press: Washington, DC.
45. Wu RW. 2001. The combination of antipsychotics and anticholinergic medication. Chin Clin Doct 29: 33-34.
46. Yip KC, Ungvari GS, Cheung HK, Ng FS, Lau ST. 1997. A survey of antipsychotic treatment for schizophrenia in Hong Kong. Chin Med J (Engl) 110: 792-796.
47. Young CR, Longhurst JG, Bowers MB, Jr, Mazure CM. 1997. The expanding indications for clozapine. Exp Clin Psychopharmacol 5: 216-234.